GetTopicDetailResponse(id=a7381e7586, topicName=abrocitinib, introduction=abrocitinib, content=null, image=null, comments=2, allHits=1823, url=https://h5.medsci.cn/topic?id=1775, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=94894, tagList=[TagDto(tagId=94894, tagName=abrocitinib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2265264, encodeId=86ba226526418, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a> <a href='/topic/show?id=313311242e4b' target=_blank style='color:#2F92EE;'>#中重度特應性皮炎#</a>, objectTitle=J Allergy Clin Immunol Pract：特應性皮炎治療新警示！青少年 vs 老年人，JAK 抑制劑 Abrocitinib 老年患者（≥65 歲）用藥風險顯著升高，劑量選擇需謹慎, objectType=article, longId=877682, objectId=d2a88e76829d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241227/1735286755162_8538692.png, objectUrl=/article/show_article.do?id=d2a88e76829d, replyNumber=0, likeNumber=25, createdTime=2025-05-16, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d2a88e76829d, moduleTitle=J Allergy Clin Immunol Pract：特應性皮炎治療新警示！青少年 vs 老年人，JAK 抑制劑 Abrocitinib 老年患者（≥65 歲）用藥風險顯著升高，劑量選擇需謹慎, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d2a88e76829d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2218952, encodeId=90a42218952a1, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a> <a href='/topic/show?id=313311242e4b' target=_blank style='color:#2F92EE;'>#中重度特應性皮炎#</a>, objectTitle=Am J Clin Dermatol：Abrocitinib在中重度特應性皮炎患者中長期安全性, objectType=article, longId=837897, objectId=38c583e89792, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240806/1722949266153_5485250.jpg, objectUrl=/article/show_article.do?id=38c583e89792, replyNumber=0, likeNumber=107, createdTime=2024-08-07, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=38c583e89792, moduleTitle=Am J Clin Dermatol：Abrocitinib在中重度特應性皮炎患者中長期安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=38c583e89792)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1184894, encodeId=e725118489406, content=FDA批準了<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>, objectTitle=Abrocitinib獲得CHMP的積極意見，用于治療成人中重度特應性皮炎, objectType=article, longId=218693, objectId=91f621869309, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211015/1634310632380_5295902.jpg, objectUrl=/article/show_article.do?id=91f621869309, replyNumber=0, likeNumber=97, createdTime=2022-01-16, rootId=0, userName=病毒獵手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91f621869309, moduleTitle=Abrocitinib獲得CHMP的積極意見，用于治療成人中重度特應性皮炎, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=91f621869309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作為<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制劑#</a>也會成為<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特異性皮炎#</a>治療的選擇，未來會與單抗，PDE-5抑制劑等形成競爭，使得治療多樣化，醫(yī)生的選擇也會增加, objectTitle=Abrocitinib治療中重度特應性皮炎的III期研究：已達到主要終點, objectType=article, longId=203284, objectId=ffda20328428, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201111/1605109462465_5295902.jpeg, objectUrl=/article/show_article.do?id=ffda20328428, replyNumber=0, likeNumber=244, createdTime=2020-11-12, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffda20328428, moduleTitle=Abrocitinib治療中重度特應性皮炎的III期研究：已達到主要終點, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ffda20328428)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
